Introduction

Amlodipine is one of the most prescribed cardiovascular drugs in Nigeria and across West Africa. As a long-acting calcium channel blocker, it is used daily in hospitals, clinics, and community pharmacies to manage hypertension and angina; two of the most prevalent non-communicable diseases in the region. (1)

Despite its widespread use, errors in amlodipine dosage and monitoring remain common in clinical practice. Prescribers sometimes begin at too high a dose, overlook important drug interactions such as the amlodipine-simvastatin interaction, or fail to counsel patients adequately on what to expect. These are preventable errors.

This guide provides a comprehensive reference for clinicians and healthcare students in Nigeria: the pharmacology, correct dosing, drug interactions, adverse effects, monitoring requirements, and practical prescribing tips all within the context of West African clinical practice.

Drug Class

Amlodipine belongs to the dihydropyridine calcium channel blocker (CCB) class of antihypertensive and antianginal agents. It works by selectively blocking voltage-gated L-type calcium channels in vascular smooth muscle and cardiac muscle cells, causing vasodilation and a reduction in peripheral vascular resistance. (2)

Unlike non-dihydropyridine CCBs such as verapamil and diltiazem, amlodipine has minimal effect on cardiac conduction and is therefore preferred in patients where heart rate control is not the primary goal.

Indications

• Hypertension; first-line or add-on therapy in adults and children over six years of age
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s angina)
• Coronary artery disease; to reduce the risk of hospitalisation from angina
• Hypertension in pregnancy; used under specialist supervision as an alternative to nifedipine

Dosage

Amlodipine should be initiated at the lowest effective dose and titrated upward based on clinical response and tolerability.

Indication	Starting Dose	Maintenance Dose	Maximum Dose
Hypertension (adult)	5 mg once daily	5–10 mg once daily	10 mg/day
Angina (adult)	5 mg once daily	5–10 mg once daily	10 mg/day
Hypertension (children 6–17 years)	2.5 mg once daily	2.5–5 mg once daily	5 mg/day
Elderly patients	2.5 mg once daily	Titrate slowly	10 mg/day
Hepatic impairment	2.5 mg once daily	Titrate with caution	10 mg/day

Amlodipine can be taken with or without food. Its long half-life of 30–50 hours makes once-daily dosing effective and convenient for patients. (3)

Drug–Drug Interactions

Several drug interactions with amlodipine carry significant clinical implications. The following are the most important for clinicians in Nigeria to be aware of:

• Simvastatin: This is one of the most clinically important interactions. Amlodipine inhibits CYP3A4, the enzyme responsible for simvastatin metabolism. Co-administration increases simvastatin plasma concentrations, raising the risk of myopathy and rhabdomyolysis. The simvastatin dose should not exceed 20 mg/day when used with amlodipine. (4)
• Cyclosporin: Amlodipine increases cyclosporin blood levels. Monitor cyclosporin concentrations closely in transplant patients.
• Tacrolimus: Similar to cyclosporin, amlodipine may increase tacrolimus exposure. Dose adjustment and monitoring of tacrolimus levels are required.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): These drugs inhibit the metabolism of amlodipine, potentially increasing its plasma concentration and the risk of hypotension and peripheral oedema. Use with caution and monitor blood pressure closely.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): These drugs may significantly reduce amlodipine plasma levels, reducing its antihypertensive effect. Blood pressure should be monitored and dose adjustment may be necessary.
• Antihypertensive agents: Additive blood pressure-lowering effects may occur when amlodipine is combined with other antihypertensives, diuretics, or nitrates. Monitor for hypotension.

Adverse Effects

Amlodipine is generally well tolerated. Most adverse effects are dose-dependent and relate to its vasodilatory mechanism.

Common (affecting more than 1 in 10 patients)

• Peripheral oedema: particularly ankle swelling. This is the most frequently reported side effect and the leading cause of discontinuation. It results from arteriolar dilation increasing capillary pressure rather than fluid retention. (5)

Common (affecting 1 in 10 to 1 in 100 patients)

• Headache
• Flushing
• Dizziness
• Fatigue
• Palpitations
• Nausea

Less common

• Hypotension: More likely in elderly patients or those on combination antihypertensive therapy
• Gingival hyperplasia: Abnormal gum overgrowth with long-term use
• Skin rash
• Visual disturbances

Rare but serious

• Severe hypotension
• Angioedema
• Erythema multiforme

Monitoring & Prescribing Tips

• Blood pressure: Monitor at each clinic visit to assess therapeutic response. Target blood pressure for most adults is below 130/80 mmHg. (6)
• Heart rate: Amlodipine generally has minimal effect on heart rate, but monitor in patients on combination therapy with beta-blockers.
• Renal and hepatic function: Amlodipine is extensively hepatically metabolised. Exercise caution and start at lower doses in patients with hepatic impairment.
• Peripheral oedema: Reassure patients that ankle swelling from amlodipine is not due to heart failure. Reducing the dose or switching to a different CCB formulation may help. Do not automatically prescribe a diuretic without assessing the cause.
• Elderly patients: Begin at 2.5 mg once daily and titrate slowly due to increased sensitivity to vasodilation and risk of falls from hypotension.
• Pregnancy: Amlodipine is not the first-line calcium channel blocker in pregnancy. Nifedipine is generally preferred. Use amlodipine only under specialist guidance if nifedipine is not tolerated.

Clinical Tips

• Amlodipine’s long half-life means that if a patient misses a dose, they should take it as soon as they remember; unless it is close to the time of their next dose. Blood pressure will not spike dramatically due to the drug’s extended duration of action.
• If a patient on amlodipine and simvastatin presents with muscle pain or weakness, always consider statin-induced myopathy secondary to the drug interaction before attributing symptoms to another cause.
• Peripheral oedema is the most common reason patients self-discontinue amlodipine. Proactively counsel patients about this expected side effect at initiation to improve adherence.
• Amlodipine can safely be combined with ACE inhibitors, ARBs, and thiazide diuretics as part of combination antihypertensive regimens.

Nigeria and West Africa Context

Amlodipine is one of the five most dispensed antihypertensive medicines in Nigeria, alongside losartan, lisinopril, nifedipine, and furosemide. (7) Its affordability as a generic medicine, once-daily dosing convenience, and proven efficacy in the Black African population make it a practical and effective choice for clinicians across the region.

Hypertension control rates in Nigeria remain suboptimal, with studies showing that fewer than one in three patients achieves adequate blood pressure targets. (8) A key contributing factor is medication non-adherence, often driven by poorly managed side effects, particularly peripheral oedema from amlodipine. Structured patient education at the time of prescribing can significantly improve adherence and outcomes.

Clinicians in Nigeria should also be aware that the amlodipine-simvastatin interaction is particularly relevant in local practice, as both drugs are widely co-prescribed in patients with hypertension and dyslipidaemia. Always check the simvastatin dose when prescribing amlodipine and cap it at 20 mg/day.

Conclusion

Amlodipine remains a cornerstone of cardiovascular pharmacotherapy in Nigeria and West Africa. When prescribed at the correct amlodipine dosage, with awareness of key drug interactions and proactive patient counselling, it is a safe and highly effective antihypertensive and antianginal agent. Understanding its pharmacology, monitoring parameters, and interaction profile – especially with simvastatin – is essential for every clinician and healthcare student in the region.

Medituri CTA

Need to verify amlodipine interactions before prescribing? Use the Medituri Drug- Drug Interaction Checker to instantly check for clinically significant interactions; including the amlodipine-simvastatin combination at the point of care.

Explore the full amlodipine drug profile and thousands of other drug references in the Medituri Comprehensive Drug Database.

Visit medituri.com to access these tools today.

References

Adeloye D, Basquill C, Aderemi AV, Thompson JY, Obi FA. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. Journal of Hypertension. 2015;33(2):230–42.

Marfo AFA, Marfo JS, Plange-Rhule J, Hollingworth S. Antihypertensive medicine use differs between Ghana and Nigeria. BMC Cardiovascular Disorders. 2022;22(1):349.

Abernethy DR, Schwartz JB. Calcium-antagonist drugs. New England Journal of Medicine. 1999;341(19):1447–57.

Joint Formulary Committee. British National Formulary (BNF) 85. London: BMJ Group and Pharmaceutical Press; 2023.

Food and Drug Administration (FDA). FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2011.

Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102(13):1503–10.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104.

Hollingworth SA, Chan AHY, Onwudiwe N, Uzochukwu BSC. Antihypertensive medicine use differs between Ghana and Nigeria. BMC Cardiovascular Disorders. 2022;22:349.